4-Alkenyl Phenethylamine Derivatives for Serotonin Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic treatments, such as LSD and psilocybin, may not be suitable for all patients due to adverse reactions like headaches, nausea, anxiety, and cardiovascular stimulation, and lack alternatives with different properties to manage medical conditions effectively.
Innovation Solution
Development of 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds that interact with serotonin 5-HT2A receptors, offering alternative therapeutic options with improved efficacy and reduced adverse effects by modifying the pharmacological profile to provide more positive effects and shorter duration of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing psychedelics (LSD, psilocybin) are used for therapeutic treatment, then therapeutic efficacy is achieved, but adverse reactions occur including headaches, nausea, anxiety, and cardiovascular stimulation
Solution Approach 1:
The patent modifies the chemical structure of phenethylamine derivatives by changing parameters such as introducing 4-alkenyl or 4-alkynyl substituents, modifying the aromatic nucleus substitution patterns (2,4,5- or 2,4,6-trisubstitution), and adjusting molecular properties to achieve different pharmacological profiles that reduce adverse effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates composite molecular structures combining phenethylamine core with specific aromatic substitution patterns and side chain modifications to produce compounds with optimized pharmacological properties that balance therapeutic effects and reduce harm
2Adaptability or versatility
If DOM and related compounds are used, then psychedelic effects are achieved, but the substances are not well-suited for all patients and lack diverse pharmacological profiles
Solution Approach 1:
The patent systematically varies structural parameters including the type of substituent at the 4-position (alkenyl, alkynyl, aryl, heteroaryl), the substitution pattern on the aromatic nucleus (2,4,5- or 2,4,6-trisubstitution), and side chain modifications to generate a diverse series of compounds with different pharmacological properties suitable for different patient needs
3Productivity
If more patients need psychedelic-assisted therapy, then demand increases, but the availability of substances with different properties remains limited
Solution Approach 1:
The patent expands the available pharmacological toolkit by synthesizing and characterizing multiple novel phenethylamine derivatives with different structural parameters, enabling clinicians to select from a broader range of substances with varying efficacy and side effect profiles to match individual patient requirements as demand for therapy increases
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds induce psychoactive effects while minimizing adverse reactions, offering a safer and more effective treatment for patients who cannot tolerate existing psychedelics, with potential for improved therapeutic outcomes in substance-assisted psychotherapy.
Implementation Method 1
These compounds interact with serotonin 5-HT2A receptors, offering alternative therapeutic options with improved efficacy and reduced adverse effects
Data Source
AI summary
A composition of a compound represented by FIGS. 1A-1E for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIGS. 1A-1E to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E and changing neurotransmission in the individual.